Answers are grounded in this paper and cite their sources.
A current limiting factor within the field of lung transplantation is the availability of viable donor lungs to meet the increasing recipient demand. Exvivo lung perfusion (EVLP) is a novel technology which involves the active ventilation of lungs in a physiologic-like environment outside of the body. During EVLP, high risk donor lungs can be assessed, treated and repaired prior to transplantation. Indeed, many transplant centers have now reported comparable outcomes of using these extended criteria lungs to conventional donors through the use of EVLP. Pre-clinical studies and case reports have demonstrated EVLP as an ideal intervention for targeted therapeutics to address donor-related complications such as infection, pulmonary emboli, and aspiration-injury. In addition, increasing evidence has been put forth demonstrating that EVLP usage can extend the total length of pulmonary preservation, which may serve a variety of clinical purposes.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: